Banyu Launches Merck’s Isentress HIV Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Banyu Pharmaceutical launched in Japan the HIV treatment Isentress (raltegravir), the only drug of its kind for blocking the virus that causes AIDS. The drug works by inserting viral DNA into human DNA to inhibit the integrase enzyme. Banyu is a wholly owned subsidiary of U.S. drug maker Merck. The drug also can help HIV-infected people who have developed a resistance to other drugs. (Click here for more - a subscription may be required
You may also be interested in...
Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
Journey East: How Chinese Returnees Build Global-Bound Biopharmas
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.
Need a specific report? 1000+ reports available
Buy Reports